Third quarter financial report

07. Nov 2019 | 2 min read

Moss, 7 November 2019

Gentian Diagnostics AS announces its results for the third quarter of 2019.

The highlights include:

  • Record sales revenues of MNOK 13.1 in 3Q19, up from MNOK 10.4 in 3Q18, totaling a 26 % growth YOY
  • Record sales revenue for the first nine months of MNOK 33.9 representing 18% growth compared to the same period of 2018
  • In July, Gentian and Beckman Coulter, one of the top 5 global diagnostics companies, prolongated their partnership agreement for Cystatin C by 6 years
  • In August, Gentian announced the sales channel agreement for fCAL® turbo between Roche Diagnostics and Gentian’s sales partner Bühlmann Laboratories AG

Please find the report and results presentation here:

7th Nov 2019 - Quarterly Report - Q3

7th Nov 2019 - Quarterly Presentation - Q3

 

For further information, please contact:

Hilja Ibert
CEO, Gentian Diagnostics
E-mail: hilja.ibert@gentian.no
Cell Phone: +47 919 05 242

Njaal Kind
CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone. +47 919 06 525

 

MeldingsID: 488795

You may also read


Dec 16, 2019 - Kristin Hart

Financial calendar

Financial calendar for Gentian Diagnostics AS

Dec 05, 2019 - Kristin Hart

Gentian Diagnostics presents at DNB conference in New York

Moss 05.12.19 The CEO of Gentian Diagnostics, Dr. Hilja Ibert, will today give a company presentation at the..

Nov 29, 2019 - Kristin Hart

Share capital increase registered

Reference is made to the stock exchange notice from Gentian Diagnostics AS (the "Company") on 25 November..